Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 21, 2012, Pages 8155-8160

  Stewart, Joanna D ^a   Marchan, Rosemarie ^a   Lesjak, Michaela S ^a   Lambert, Joerg ^b   Hergenroeder, Roland ^b   Ellis, James K ^c   Lau, Chung Ho ^c   Keun, Hector C ^c   Schmitz, Gerd ^d   Schiller, Juergen ^e   Eibisch, Mandy ^e   Hedberg, Christian ^f   Waldmann, Herbert ^a,f   Lausch, Ekkehart ^g   Tanner, Berno ^h   Sehouli, Jalid ⁱ   Sagemueller, Jens ^j   Staude, Hagen ^k   Steiner, Eric ^l   Hengstler, Jan G ^a  

^a TU DORTMUND UNIVERSITY   (Germany)

^b LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h Oranienburg Clinic   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^k UNIVERSITY OF ROSTOCK   (Germany)

^l Department of Obstetrics and Gynecology   (Germany)

more..

Author keywords

Glycerophosphocholine phosphodiesterase GDE1 homolog (Saccharomyces cerevisiae); Glycerophosphodiester phosphodiesterase domain containing 6; Glycerophosphodiesterase 5; Lysophosphatidic acid; Phosphatidic acid

Indexed keywords

GLYCEROPHOSPHORYLCHOLINE; MESSENGER RNA; PHOSPHODIESTERASE; PROTEIN ED13; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM; METABOLITE; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHOLINE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; PHOSPHOLIPASES; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASE C-ALPHA; SIGNAL TRANSDUCTION;

SACCHAROMYCES CEREVISIAE;

EID: 84861428530     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117654109     Document Type: Article

References (45)

1. Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59: 80-84. (Pubitemid 29062961)
2. Ackerstaff E, Glunde K, Bhujwalla ZM (2003) Choline phospholipid metabolism: A target in cancer cells? J Cell Biochem 90:525-533. (Pubitemid 37243700)
3. Glunde K, Jie C, Bhujwalla ZM (2004) Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64:4270-4276. (Pubitemid 38802433)
4. Iorio E, et al. (2005) Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65:9369-9376. (Pubitemid 41508005)
5. Gillies RJ, Morse DL (2005) In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 7:287-326. (Pubitemid 41170190)
6. Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM (2010) Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev 110:3043-3059.
7. Iorio E, et al. (2010) Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res 70:2126-2135.
8. Negendank W (1992) Studies of human tumors by MRS: A review. NMR Biomed 5: 303-324.
9. Podo F (1999) Tumour phospholipid metabolism. NMR Biomed 12:413-439.
10. Eliyahu G, Kreizman T, Degani H (2007) Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies. Int J Cancer 120:1721-1730. (Pubitemid 46402874)
11. Ramírez de Molina A, et al. (2002) Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene 21: 4317-4322.
12. Ramírez de Molina A, et al. (2002) Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296:580-583.
13. Hernández-Alcoceba R, Fernández F, Lacal JC (1999) In vivo antitumor activity of choline kinase inhibitors: A novel target for anticancer drug discovery. Cancer Res 59: 3112-3118. (Pubitemid 29316010)
14. Katz-Brull R, Degani H (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16(3B):1375-1380.
15. Kouji H, et al. (2009) Molecular and functional characterization of choline transporter in human colon carcinoma HT-29 cells. Arch Biochem Biophys 483:90-98.
16. Noh DY, et al. (2000) Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161:207-214.
17. Zhong M, et al. (2003) Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 302: 615-619. (Pubitemid 36279575)
18. Guthridge CJ, Stampfer MR, Clark MA, Steiner MR (1994) Phospholipases A2 in rastransformed and immortalized human mammary epithelial cells. Cancer Lett 86: 11-21.
19. Yamashita S, Yamashita J, Ogawa M (1994) Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69:1166-1170. (Pubitemid 24161881)
20. Yanaka N (2007) Mammalian glycerophosphodiester phosphodiesterases. Biosci Biotechnol Biochem 71:1811-1818.
21. Okazaki Y, et al. (2010) A novel glycerophosphodiester phosphodiesterase, GDE5, controls skeletal muscle development via a non-enzymatic mechanism. J Biol Chem 285:27652-27663.
22. Gallazzini M, Ferraris JD, Burg MB (2008) GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci USA 105:11026-11031.
23. Cao MD, et al. (2012) Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed, 10.1002/nbm2766.
24. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674.
25. Wang P, et al. (2001) Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases. Life Sci 68:1977-1987. (Pubitemid 32245599)
26. Yalcin A, et al. (2010) Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 29:139-149.
27. Exton JH (1990) Signaling through phosphatidylcholine breakdown. J Biol Chem 265: 1-4.
28. Kam Y, Exton JH (2004) Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid. FASEB J 18:311-319. (Pubitemid 38186250)
29. Kang DW, et al. (2008) Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J Biol Chem 283: 4094-4104.
30. Kang DW, et al. (2011) Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells. Int J Cancer 128:805-816.
31. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591. (Pubitemid 37328830)
32. Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614.
33. Scott SA, et al. (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol 5:108-117.
34. Narayan P, Dahiya R (1991) Alterations in sphingomyelin and fatty acids in human benign prostatic hyperplasia and prostatic cancer. Biomed Biochim Acta 50: 1099-1108.
35. Foster DA (2009) Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. Biochim Biophys Acta 1791:949-955.
36. Cheng CY, et al. (2009) IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells. J Cell Physiol 219:183-193.
37. Guo J, et al. (2008) Nicotine promotes mammary tumor migration via a signaling cascade involving protein kinase C and CDC42. Cancer Res 68:8473-8481.
38. Ng T, et al. (1999) PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J 18:3909-3923. (Pubitemid 29335844)
39. American Cancer Society (2010) Cancer Facts and Figures 2010 (American Cancer Society, Atlanta).
40. Steiner E, et al. (2003) Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 13:197-203. (Pubitemid 37055478)
41. Keun HC, Athersuch TJ (2011) Nuclear magnetic resonance (NMR)-based metabolomics. Methods Mol Biol 708:321-334.
42. Ecker J, et al. (2010) Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. Proc Natl Acad Sci USA 107: 7817-7822.
43. Leidl K, Liebisch G, Richter D, Schmitz G (2008) Mass spectrometric analysis of lipid species of human circulating blood cells. Biochim Biophys Acta 1781:655-664.
44. Micke P, et al. (2003) Characterization of c-kit expression in small cell lung cancer: Prognostic and therapeutic implications. Clin Cancer Res 9:188-194. (Pubitemid 36109732)
45. Micke P, et al. (2001) c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 92:474-479. (Pubitemid 32319418)